Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ATP4AATP4BAXLBTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CHRM2CHRM3CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4FLT3HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3KCNH2KMT2AMAP2K1MAP2K2MEN1MLNRMPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PLK4PPARGRENS1PR1SLC6A2SLC6A3SLC6A4SMOTYK2atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A known ✓ | P35348 | 3/20 | 0.40 |
| ▸ | SLC6A3 known ✓ | Q01959 | 3/20 | 0.40 |
| ▸ | CACNA1C known ✓ | Q13936 | 3/20 | 0.40 |
| ▸ | HTR1A known ✓ | P08908 | 2/20 | 0.40 |
| ▸ | ADRA2A known ✓ | P08913 | 2/20 | 0.40 |
| ▸ | DRD1 known ✓ | P21728 | 2/20 | 0.40 |
| ▸ | SLC6A2 known ✓ | P23975 | 2/20 | 0.40 |
| ▸ | KCNH2 known ✓ | Q12809 | 2/20 | 0.40 |
| ▸ | EGFR known ✓ | P00533 | 1/20 | 0.40 |
| ▸ | ERBB2 known ✓ | P04626 | 1/20 | 0.40 |
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.40 |
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.40 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.40 |
| ▸ | ADRA1D known ✓ | P25100 | 1/20 | 0.40 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.40 |
| ▸ | ADRA1B known ✓ | P35368 | 1/20 | 0.40 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.40 |
| ▸ | CACNA1F known ✓ | O60840 | 1/20 | 0.39 |
| ▸ | CACNA1D known ✓ | Q01668 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Maleic Acid SCHEMBL6296545 | 1.00 | TSHR (0.42) | TSHRPOLBALDH1A1LMNATBXA2R | |
| SCHEMBL6293656 | 0.84 | CACNA1C (0.52) | CACNA1CCACNA1FCACNA1DCACNA1S | |
| SCHEMBL6297236 | 0.84 | MEN1 (0.44) | TSHRALDH1A1CACNA1CBCHECACNA1F | |
| SCHEMBL6292278 | 0.83 | ADORA3 (0.47) | TSHRALDH1A1CACNA1CADORA3EGFR | |
| SCHEMBL6296647 | 0.82 | GAA (0.49) | TSHRPOLBALDH1A1LMNACACNA1C | |
| SCHEMBL6296464 | 0.81 | TSHR (0.56) | TSHRPOLBALDH1A1LMNATBXA2R | |
| SCHEMBL6296612 | 0.81 | MAPT (0.48) | CACNA1CMEN1KMT2AGAAMAPT | |
| SCHEMBL6293440 | 0.80 | ADORA3 (0.47) | TSHRPOLBALDH1A1LMNATBXA2R | |
| SCHEMBL6293641 | 0.80 | ABCC1 (0.53) | TSHRALDH1A1LMNACACNA1CEGFR | |
| SCHEMBL6292316 | 0.80 | TSHR (0.47) | TSHRPOLBALDH1A1LMNATBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6977262-B2 | Dihydropyrazolopyridine compounds and pharmaceutical use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2005-12-20 | — | — | US | disclosed |
| US-20040052822-A1 | Dihydropyrazolopyridine compounds and pharmaceutical use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2004-03-18 | — | — | US | disclosed |
| EP-1355909-A2 | DIHYDROPYRAZOLOPYRIDINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2003-10-29 | — | — | EP | disclosed |
| WO-2002062795-A2 | DIHYDROPYRAZOLOPYRIDINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | MITSUBISHI PHARMA CORPORATION (JP) | 2002-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040052822-A1 | Dihydropyrazolopyridine compounds and pharmaceutical use thereof | GSK3B, GSK3A, PYGB | ADRA1A 1189/4885SLC6A3 560/4885CACNA1C 358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.